Ductal adenocarcinoma of the pancreas, commonly known as pancreatic cancer, has a poor prognosis with a median overall survival of 6 months. It currently represents the fourth commonest cause of cancer-related death. Poor survival of pancreatic cancer patients is a consequence of late diagnosis and pronounced chemoresistance.
Our group investigates the role of tumour-stoma interactions, (intra-)tumour heterogeneity, genomics and metabolomics in the development of chemoresistance. Investigations are based on culture models of primary human cancer/stromal cells and human tumour tissue.